HCPLive

Prenatal Vitamin C Cuts Wheeze in Babies of Smokers

MONDAY, May 6 (HealthDay News) -- For women who smoke, vitamin C supplementation during pregnancy is associated with reduced incidence of wheezing in their offspring through the age of 1 year, according to a study presented at the annual meeting of the Pediatric Academic Societies, held from May 4 to 7 in Washington, DC.

Cindy T. McEvoy, MD, from the Oregon Health & Science University, in Portland, and colleagues examined the impact of supplemental daily vitamin C during pregnancy on the incidence of wheezing within the first year of life. The infants of 76 smokers randomized to vitamin C, the infants of 83 smokers randomized to placebo, and the infants of 76 nonsmokers were assessed at delivery. Ninety-two percent were followed through age 1.

The researchers found that significantly fewer infants of vitamin-C treated versus placebo-treated smokers had at least one episode of wheezing (21 versus 40 percent; adjusted P = 0.019) and fewer infants received medication for wheezing (13 versus 22 percent; adjusted P = 0.14). The incidence of wheezing was significantly lower for those randomized to vitamin C versus placebo for infants of pregnant smokers homozygous or heterozygous for the rs16969968 risk allele (14 versus 48 percent; P = 0.01).

"Vitamin C is a simple, safe, and inexpensive treatment that may decrease the impact of smoking during pregnancy on childhood respiratory health," McEvoy said in a statement. "Though the lung function of all babies born to smokers in our study was improved by supplemental vitamin C, our preliminary data suggest that vitamin C appeared to help those babies at the greatest risk of harm during their development from their mother's smoking in pregnancy."

Press Release
More Information

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Almost half a million Americans were infected with the bacteria Clostridium difficile in 2011, and 29,000 died within a month of diagnosis, US health officials say. The report is published in the Feb. 26 issue of the New England Journal of Medicine.
Actavis PLC and Medicines360, a nonprofit women's health pharmaceutical company, announced that the US Food and Drug Administration (FDA) has granted approval of Liletta (levonorgestrel-releasing intrauterine system), an intrauterine device (IUD) providing up to 3 years of safe and effective contraception.
After undergoing weight-loss surgery, women are significantly less prone to diabetes during pregnancy but twice as likely to deliver smaller-than-normal infants, according to a study published in the Feb. 26 issue of the New England Journal of Medicine.
Addicts' use of a powerful painkiller is driving a large HIV outbreak in Indiana, according to health officials.
$vAR$